Golvatinib + Lenvatinib + Lenvatinib
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Oct 13, 2011 → Mar 1, 2017
NCT ID
NCT01433991About Golvatinib + Lenvatinib + Lenvatinib
Golvatinib + Lenvatinib + Lenvatinib is a phase 1/2 stage product being developed by Eisai for Advanced Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT01433991. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01433991 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumors